Topics

Companies Related to "Cystic fibrosis Pricing Market Access Published First View" [Most Relevant Company Matches] RSS

17:11 EST 19th February 2020 | BioPortfolio

Here are the most relevant search results for "Cystic fibrosis Pricing Market Access Published First View" found in our extensive corporate database of over 50,000 company records.

Showing "Cystic fibrosis Pricing Market Access Published First View" Companies 1–25 of 6,300+

Extremely Relevant

Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Instit...


Cystic Fibrosis Foundation, Northern Ohio Chapter

The Northern Ohio Chapter of the Cystic Fibrosis Foundation works to help develop a means to control and cure cystic fibrosis and to improve the lives of those with the disease. The chapter serves 28 counties throughout Northern Ohio.

Cystic Fibrosis Trust

•        Cystic fibrosis is chronically misunderstood, kills thousands worldwide and is carried unknowingly in the genes of millions. It's often invisible to the naked eye yet destroys lives, stopping them short, inflicting hardship and distress on patients, their families and carers. Cystic fibrosis directly affects around 10,000 people in the UK. &b...


BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operat...

RJW & Partners

RJW & Partners was founded in 2008 and is a consultancy with unique capabilities in pricing and market access, focused solely on the pharmaceutical and healthcare sectors. All senior staff have worked at the highest levels in pricing and market access in either government or industry and throughout their consulting careers have personally advised on the pr...

New Lung Associates

New Lung Associates is a pulmonary group of physicians leading the Lung Transplant Program and the Adult Cystic Fibrosis Program at Tampa General Hospital, a 988-bed acute care hospital in Tampa, Fla. The New Lung Associates team has specialized focus in the care of advanced lung diseases, cystic fibrosis, and lung transplantation. New Lung Associatesâ€...

Relevant

The Cystic Fibrosis Foundation

Talee Bio, Inc.

Talee Bio is a development stage biopharmaceutical company focused on developing gene therapy products for the treatment of cystic fibrosis. The company is developing two inhaled gene therapy drug candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentivirus gene therapy. The company was founded by...

ABPPC Ltd

ABPPC Ltd is a pharmaceutical consultancy specialised in supporting drug commercialisation through integrated approaches to pricing, reimbursement and market access Our Staff Director of the company Adam Barak formerly headed Pricing & Reimbursement at GlaxoWellcome Europe and was Head of International Pricing & Reimbursement at biotech company OGS. ABPPC comprises an international network of coun...

SciClone Pharmaceuticals

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cancer, immune system disorders and cystic fibrosis.

Cystic Fibrosis Enters the Proteomics Scene

As a continuation to genomic research, proteomics now offers the unique advantage to examine global alterations in the protein expression patterns of CF cells and tissues. The systematic use of proteomics should ultimately result in the finding of new prognostic markers...

ZappRx, Inc.

ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payer...

Pharmaxis Ltd

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is launched in a number of key markets. Its development pipeline of products includes: Bronchitol for cystic fibrosis, b...

Axentis Pharma AG

Axentis Pharma is a Swiss-based pharmaceutical company focused on chronic lung diseases and respiratory related disorders, especially on cystic fibrosis. Axentis Pharma is solely financed by private investors. The company is currently looking for co-development and co-marketing partners in the respiratory arena with the goal to create a competence center for healthcare professionals and patients...

ZappRx

ZappRx simplifies the complex process required to order specialty medications, making it easier to collect and save all of the information required to order a prescription — including pharmacy information, payer/prior authorization requirements, and relevant patient clinical history. ZappRx then enables providers, pharmacists, and payers to digitally ...

PillBot.com

PillBot.com was created to assist consumers in obtaining competitive pricing when shopping for online prescriptions. Pricing is one of the most requested criteria when shopping for prescriptions. In addition, there are many factors that concern consumers when shopping for prescriptions online such as; customer service, shipping costs, insurance coverage and access to a pharmacist. PillBot.com prov...

PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Boomer Esiason Foundation and Adorama

BEF supports the cystic fibrosis community through scholarships, transplant grants, exercise programs, and educational programs as well as funding CF research. To date, BEF has raised over $130 million. Please visit Esiason.org to learn more about our programs, teamboomer.org to join the team, and follow us at facebook.com/BoomerEsiasonFoundation an...

AmpliPhi BioSciences Corporation

AmpliPhi Biosciences Corporation (AmpliPhi) is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform. Our lead product development programs target Gram negative bacterial infections that are often resistant to existing antibiotic treatments. They include BioPhage-PA f...

Aradigm Corporation

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of cystic fibrosis, bronchiectasis, inhaled bioterrorism infections and smoki...

ELITechGroup Biomedical Systems

ELITechGroup Biomedical Systems (EBS) is the world leader for laboratory diagnosis of cystic fibrosis with the proven products for sweat stimulation, collection, and analysis. The company is also a key player in supporting global laboratories with the world’s most advanced cytocentrifuge rotor, slide stainers, and osmometers.

Coalition for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thir...

HealthStyle Press

For over 20 years, HealthStyle Press has published America’s Health Guides™health education booklets for every stage of life. Our health guide content is gathered from trusted medical sources, such as the American Academy of Pediatrics, CDC, US Preventive Services Task Force and more. We continuously review and update our content as the latest gu...

HealthyChildrenToday.com

HealthyChildrenToday.com is committed to providing the latest and most relevant information for children with respiratory issues or compromised immune systems. Visitors can read the most recent articles on topics ranging from asthma and allergies to cystic fibrosis and premature infants. The site's Med Blog and MedTech Blog showcase commentary from concerned parents, technology researchers, and to...

LABSCAN

In 1984, a time when there was not much manufacturing in Ireland, and little or no associated technology, Labscan was set up, with a view to providing high-end technical support to a burgeoning chemical industry. The strategy from the beginning was clear: focus on a niche market, invest seriously - and continually - in research and development, and provide Labscan customers with quality and compet...


More From BioPortfolio on "Cystic fibrosis Pricing Market Access Published First View"

Quick Search

Corporate Database Quicklinks